So what the heck happened with the blockbuster Humira, in that case ... researchers have been slow to switch over. That poses a risk of mix-up, but also erodes patients’ trust in their care ...

Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

AbbVie’s promising pipeline and 3.95% dividend yield offer growth potential. Read why ABBV stock could thrive despite the Emraclidine trial failure.